Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press133910.17650/1726-9776-2021-17-1-134-141REVIEWОБЗОРClinical and morphological features of non-muscle invasive bladder cancer: implications for treatment, prognosis and relapse of the disease (literature review)Клинико-морфологические особенности немышечноинвазивного рака мочевого пузыря: влияние на лечение, прогноз и рецидив заболевания (обзор литературы)https://orcid.org/0000-0002-4424-3261PshikhachevA. M.ПшихачевА. М.
Russian Federation

Build. 10, 27 Lomonosovskiy Prospekt, Moscow 119192.

Пшихачев Ахмедхан Мухамедович - доктор медицинских наук, старший научный сотрудник, врач-уролог МНОЦ МГУ им. М.В. Ломоносова, врач-уролог, онколог ГКБ №31.

119192 Москва, Ломоносовский проспект, 27, корп. 10.

pshich@yandex.ruhttps://orcid.org/0000-0003-2052-914XMikhalevaL. M.МихалеваЛ. М.
Russian Federation

3 Tsyurupy St., Moscow 117418.

Михалева Людмила Михайловна - директор НИИ морфологии человека; заведующая лабораторией клинической морфологии НИИ морфологии человека; заведующая патологоанатомическим отделением ГКБ № 31 ДЗМ, доктор медицинских наук, профессор.

117418 Москва, ул. Цюрупы, 3.

mikhalevalm@yandex.ruhttps://orcid.org/0000-0001-9538-8869GusnievM. A.ГусниевМ. А.
Russian Federation

3 Tsyurupy St., Moscow 117418.

117418 Москва, ул. Цюрупы, 3.

https://orcid.org/0000-0001-5896-4556PechnikovaV. V.ПечниковаВ. В.
Russian Federation

3 Tsyurupy St., Moscow 117418.

117418 Москва, ул. Цюрупы, 3.

PolyankoN. I.ПолянкоН. И.
Russian Federation

9 Sharikopodshipnikovskaya St., Moscow 115088.

115088 Москва, ул. Шарикоподшипниковская, 9.

https://orcid.org/0000-0001-9466-7567SorokinN. I.СорокинН. И.
Russian Federation

Build. 10, 27 Lomonosovskiy Prospekt, Moscow 119192.

119192 Москва, Ломоносовский проспект, 27, корп. 10.

https://orcid.org/0000-0003-4251-7545KamalovA. A.КамаловА. А.
Russian Federation

Build. 10, 27 Lomonosovskiy Prospekt, Moscow 119192.

Камалов Арамис Альбертович - директор Университетской клиники МГУ имени М.В. Ломоносова, академик РАН, профессор, доктор медицинских наук, заведующий кафедрой урологии и андрологии ФФМ МГУ имени М.В. Ломоносова.

119192 Москва, Ломоносовский проспект, 27, корп. 10.

Info@mc.msu.ruMedical Research and Educational Center, Lomonosov Moscow State UniversityМедицинский научно-образовательный центр Московского государственного университета им. М.В. ЛомоносоваResearch Institute of Human MorphologyНаучно-исследовательский институт морфологии человекаDepartment of Pathology, Research Institute of Health Organization and Medical Management, Moscow Healthcare DepartmentОтдел патологической анатомии ГБУ г. Москвы «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента Департамента здравоохранения г. Москвы»060520211711341411908202018022021https://oncourology.abvpress.ru/oncur/article/view/1339

This review of bladder cancer describes modern clinical and pathologic features of the neoplasm, reports new data about treatment and prognosis of this disease.

В настоящем обзоре описаны современные клинические и патоморфологические особенности рака мочевого пузыря, а также приведены данные о современных принципах лечения этого заболевания и критериях прогноза.

bladder cancernon-muscle invasive canceroncologymorphologyрак мочевого пузырянемышечно-инвазивный раконкологияморфологияKamat A.M., Bagcioglu M., Huri E. What is new in non-muscle-invasive bladder cancer in 2016? Turk J Urology 2017;43(1):9-13. DOI: 10.5152/tud.2017.60376.Anastasiadis A., de Reijke T.M. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol 2012;4(1):13-32. DOI: 10.1177/1756287211431976.State of oncological care in Russia in 2018. Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMITS radiologii” Minzdrava Rossii, 2019. 236 p. (In Russ.).Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 236 с.Axel E.M., Matveev V.B. Statistics of malignant tumors of urinary and male urogenital organs in Russia and the countries of the former USSR. Onkourologiya = Cancer Urology 2019;15(2):15-24. (In Russ.). DOI: 10.17650/1726-9776-2019-15-2-15-24.Аксель Е.М., Матвеев В.Б. Статистика злокачественных новообразований мочевых и мужских половых органов в России и странах бывшего СССР. Онкоурология 2019;15(2):15-24. DOI: 10.17650/1726-9776-2019-15-2-15-24.Hendricksen K., Witjes J.A. Treatment of Intermediate-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC). Eur Urol Suppl 2007;6(14):800-8. DOI: 10.1016/j.eursup.2007.04.008.Kassouf W., Traboulsi S.L., Kulkarni G.S. et al. CUA guidelines on the management of non-muscle invasive bladder cancer. Can Urol Assoc J 2015;9(9-10):690-704. DOI: 10.5489/cuaj.3320.Biluts H., Minas E. Bladder Tumours at Tikur Anbessa Hospital in Ethiopia. East Central African J Surgery 2011;16(1). Available at: https://www.ajol.info/index.php/ecajs/article/view/72487.Adeloye D., Harhay M.O., Ayepola O.O. et al. Estimate of the incidence of bladder cancer in Africa: a systematic review and Bayesian meta-analysis. Int J Urol 2019;26(1):102-12. DOI: 10.1111/iju.13824.Shen P.L., Lin M.E., Hong Y.K. et al. Bladder preservation approach versus radical cystectomy for high-grade non-muscle-invasive bladder cancer: a meta-analysis of cohort studies. World J Surg Oncol 2018;16(1):197. DOI: 10.1186/s12957-018-1497-0.Abdollah F., Gandaglia G., Thuret R. et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol 2013;37(3):219-25. DOI: 10.1016/j.canep.2013.02.002.Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67(1):7-30. DOI: 10.3322/caac.21387.Moschini M., D'Andrea D., Korn S. et al. Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol 2017;14(11):651-68. DOI: 10.1038/nrurol.2017.125.Baumeister P., Zamboni S., Mattei A. et al. Histological variants in nonmuscle invasive bladder cancer. Transl Androl Urol 2019;8(1):34-8. DOI: 10.21037/tau.2019.01.09.Audenet F., Attalla K., Sfakianos J.P. The evolution of bladder cancer genomics: What have we learned and how can we use it? Urol Oncol 2018;36(7):313-20. DOI: 10.1016/j.urolonc.2018.02.017.Amin M.B., McKenney J.K. An approach to the diagnosis of flat intraepithelial lesions of the urinary bladder using the World Health Organization/International Society of Urological Pathology consensus classification system. Adv Anatomic Pathol 2002;9(4):222-32. DOI: 10.1097/00125480-200207000-00002.Humphrey P.A., Moch H., Cubilla A.L. et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol 2016;70(1):106-19. DOI: 10.1016/j.eururo.2016.02.028.Felix A.S., Soliman A., Wilson M. et al. The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer Causes Control 2008;19(4):421-9. DOI: 10.1007/s10552-007-9104-7.Manunta A., Vincendeau S., Kiriakou G. et al. Non-transitional cell bladder carcinomas. BJU international 2005;95(4):497-502. DOI: 10.1111/j.1464-410X.2005.05327.x.Abol-Enein H., Kava B.R., Carmack A.J.K. Nonurothelial cancer of the bladder. Urology 2007;69(1):93-104. DOI: 10.1016/j.urology.2006.08.1107.El-Mekresh M.M., el-Baz M.A., Ghoneim M.A. et al. Primary adenocarcinoma of the urinary bladder: a report of 185 cases. Br J Urol 1998;82(2):206-12. DOI: 10.1046/j.1464-410x.1998.00718.x.Grignon D.J., Ro J.Y., Ayala A.G. et al. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 1991;67(8):2165-72. DOI: 10.1002/1097-0142(19910415)67:8<2165::aid-cncr2820670827>3.0.co;2-m.Sved P., Gomez P., Manoharan M. et al. Small cell carcinoma of the bladder. BJU Int 2004;94(1):12-7. DOI: 10.1111/j.1464-410X.2003.04893.x.Hansel D.E., Amin M.A., Comperat E. et al. A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol 2013;63(2):321-32. DOI: 10.1016/j.eururo.2012.10.008.Cheng L., Zhang S., Alexander R. et al. Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. Am J Surg Pathol 2011;35(5):34-46. DOI: 10.1097/PAS.0b013e3182159dec.Amin M.B., Ro J.Y., el-Sharkawy T. et al. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 1994;18(12):1224-32. DOI: 10.1097/00000478-199412000-00005.Moschini M., Dell'Oglio P., Luciano R. et al. Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urol Oncol 2017;35(6):335-41. DOI: 10.1016/j.urolonc.2016.12.006.Beltran A.L., Cheng L., Montironi R. et al. Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. Virchows Arch 2014;465(2):199-205. DOI: 10.1007/s00428-014-1601-y.Talbert M.L., Young R.H. Carcinomas of the urinary bladder with deceptively benign-appearing foci. A report of three cases. Am J Surg Pathol 1989;13(5):374-81. DOI: 10.1097/00000478-19890500000004.Young R.H., Oliva E. Transitional cell carcinomas of the urinary bladder that may be underdiagnosed. A report of four invasive cases exemplifying the homology between neoplastic and non-neoplastic transitional cell lesions. Am J Surg Pathol 1996;20(12):1448-54. DOI: 10.1097/00000478-199612000-00003.Gofrit O.N., Pode D., Pizov G. et al. The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Guerin immunotherapy. Urol Oncol 2009;27(3):258-62. DOI: 10.1016/j.urolonc.2007.12.011.Yang Z., Epstein J.I. Urothelial carcinoma in situ of the bladder with glandular differentiation: report of 92 cases. Am J Surg Pathol 2018;42(7):971-6. DOI: 10.1097/PAS.0000000000001073.Reis H., Krafft U., Niedworok C. et al. Biomarkers in urachal cancer and adenocarcinomas in the bladder: a comprehensive review supplemented by own data. Dis Markers 2018;2018:7308168. DOI: 10.1155/2018/7308168.Wick M.R. Primary lesions that may imitate metastatic tumors histologically: a selective review. Sem Diagn Pathol 2018;35(2):123-42. DOI: 10.1053/j.semdp.2017.11.010.Cheng L., Cheville J.C., Neumann R.M. et al. Flat intraepithelial lesions of the urinary bladder. Cancer 2000;88(3):625-31.Murata S., Iseki M., Kinjo M. et al. Molecular and immunohistologic analyses cannot reliably solve diagnostic variation of flat intraepithelial lesions of the urinary bladder. Am J Clin Pathol 2010;134(6):862-72. DOI: 10.1309/AJCPACNUDWEN9GN4.McKenney J.K. Precursor lesions of the urinary bladder. Histopathology 2019;74(1):68-76. DOI: 10.1111/his.13762.Babjuk M., Burger M., Comperat E.M. et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol 2019;76(5):639-57. DOI: 10.1016/j.eururo.2019.08.016.Kirkali Z., Chan T., Manoharan M. et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(6 Suppl 1):4-34. DOI: 10.1016/j.urology.2005.07.062.Dobruch J., Borowka A., Herr H.W. Clinical value of transurethral second resection of bladder tumor: systematic review. Urology 2014;84(4):881-5. DOI: 10.1016/j.urology.2014.06.005.Schroeck F.R., Lynch K.E., Li Z. et al. The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, nonmuscle-invasive bladder cancer. Cancer 2019;125(18):3147-54. DOI: 10.1002/cncr.32185.Semenov E.V., Mazaev A.V., Zukov R.A., Kurtasova L.M. Prognostic factors in patients at urinary bladder cancer. Sibirskoe meditsinskoe obozrenie = Siberian Medical Review 2015;(5):13-22. (In Russ.). DOI: 10.20333/25000136-2015-5-13-22.Семенов Э.В., Мазаев А.В., Зуков Р.А., Куртасова Л.М. Факторы прогноза у больных раком мочевого пузыря. Сибирское медицинское обозрение 2015;(5):13-22. DOI: 10.20333/25000136-2015-5-13-22.Simon M., Bosset P.O., Rouanne M. et al. Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score. PloS One 2019;14(2):e0211721. DOI: 10.1371/journal.pone.0211721.Aydin M., Bitkin A., Kadihasanoglu M. et al. Correlation of neutrophil-lymphocyte ratio and risk scores in non-muscle invasive bladder cancer. Actas Urol Esp 2019;43(9):503-8. DOI: 10.1016/j.acuro.2018.12.004.Sinitsina O.V., Chonkina A.A., Ilyushkina M.V. et al. Molecular genetic technique for assessing the risk of an unfavorable course of the disease in superficial bladder cancer. Meditsinskiy alfavit = Medical Alphabet 2014;3(15):56-7. (In Russ.).Синицина О.В., Чонкина А.А., Илюшкина М.В. и др. Молекулярно-генетическая методика оценки риска неблагоприятного течения заболевания при поверхностном раке мочевого пузыря. Медицинский алфавит 2014;3(15):56-7.Lee A., Lee H. J., Huang H.H. et al. Low-risk non-muscle-invasive bladder cancer: Further prognostic stratification into the “very-low-risk” group based on tumor size. Int J Urol 2019;26(4):481-6. DOI: 10.1111/iju.13913.Morera D.S., Hasanali S.L., Belew D. et al. Clinical parameters outperform molecular subtypes for predicting outcome in bladder cancer: results from multiple cohorts, including TCGA. J Urol 2020;203(1):62-72. DOI: 10.1097/JU.0000000000000351.Vorobtsova I.E., Vasilyeva Z.Z., Kouzova E.D., Timofeyev D.A., Shkolnik M.I., Odintsova M.V., Zharinov G.M. Diagnosis of recurrent bladder cancer by fluorescence in situ hybridization assay on urine sediment cells. Onkourologiya = Cancer Urology 2013;9(2):35-41. (In Russ.). DOI: 10.17650/1726-9776-2013-9-2-35-41.Воробцова И.Е., Васильева З.Ж., Коузова Е.Д. и др. Диагностика рецидивов рака мочевого пузыря с помощью FISH-метода, осуществляемого на клетках осадка мочи. Онкоурология 2013;9(2):35-41. DOI: 10.17650/1726-9776-2013-9-2-35-41.Dadhania V., Zhang M., Zhang L. et al. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine 2016;12:105-17. DOI: 10.1016/j.ebiom.2016.08.036.Kessel K.E.M., van der Keur K.A., Dyrskj0t L. et al. Molecular markers increase precision of the European Association of Urology non-muscle-invasive bladder cancer progression risk groups. Clin Cancer Res 2018;24(7):1586-93. DOI: 10.1158/1078-0432.CCR-17-2719.Al-Maghrabi J.A., Qureshi I.A., Khabaz M.N. Immunhistochemical expression of GLUT1 is associated with low grade and low stage of urinary bladder cancer. Int J Clin Exp Pathol 2019;12(8):3049-57.Yasui M., Kawahara T., Izumi K. et al. Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer. BMC Cancer 2019;19(1):331. DOI: 10.1186/s12885-019-5512-9.Chen M.K., Chen Z.J., Xiao K.H. et al. Predictive value of cadherin-11 for subsequent recurrence and progression in non-muscle invasive bladder cancer. Japan J Clin Oncol 2020;4(50):456-64. DOI: 10.1093/jjco/hyz186.Descotes F., Kara N., Decaussin-Petrucci M. et al. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine. Br J Cancer 2017;117(4):583-7. DOI: 10.1038/bjc.2017.210.He Y., Wang N., Zhou X. et al. Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review. BMJ Open 2018;8(4):e019635. DOI: 10.1136/bmjopen-2017-019635.Mossanen M., Wang Y., Szymaniak J. et al. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World J Urol 2019;37(10):2059-65. DOI: 10.1007/s00345-018-2550-x.